GSK says RSV vaccine protects against disease over three seasons
WEB20 hours ago · The results come from a large Phase 3 trial that supported Arexvy’s approval. Approximately 25,000 people in 17 countries were enrolled in the study, which compared Arexvy to placebo at several time points. Researchers calculated Arexvy’s efficacy against RSV-caused lower respiratory tract disease as 83% during the first season.
GSK presents positive data for AREXVY, its respiratory syncytial …
WEBIndication for AREXVY. AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 60 years of age and older; Individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV. Important Safety Information for ...
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower …
WEB20 hours ago · GSK on Tuesday unveiled fresh data from the late-stage AReSVi-006 study of Arexvy in older adults over the span of three full RSV seasons. In the trial, which looked at Arexvy’s ability to stop ...
GSK RSV shot 43% effective against severe disease in third year
WEB1 day ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · GSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50 to 59, including those at increased risk of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD ...
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time. The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy ...
GSK's RSV Vaccine Offers Protection Over Three Seasons, Study …
WEB1 day ago · The British pharmaceutical giant said a phase 3 trial showed Arexvy's efficacy after a single dose over three full RSV seasons stood at 62.9% against respiratory syncytial virus-lower respiratory ...
- Some results have been removed